- NCIt
- C7707
Loading cancer entity…
Loading cancer entity…
Clinical trials
76 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (15)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT02701153 | Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort | recruiting | N/A | 51 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 |
| clinicaltrials |
| NCT04671693 | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.(PASCA) | active not recruiting | N/A | 500 | Centre Leon BerardOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT01586104 | Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases | completed | N/A | 20 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT00020267 | Vaccine Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02565498 | Preoperative vs Postoperative IMRT for Extremity/Truncal STS | active not recruiting | Phase 3 | 210 | Mount Sinai Hospital, CanadaOTHER | 3 | Feb 20, 2024 | clinicaltrials |
| NCT02384473 | Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma | completed | Early Phase 1 | 25 | University of Southern CaliforniaOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT03056001 | Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma | completed | Phase 2 | 30 | Wake Forest University Health SciencesOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT00019968 | Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 0 | Oct 31, 2023 | clinicaltrials |
| NCT05684874 | Multiparametric Quantitative MRI and Response to Neoadjuvant Radiotherapy for Soft-tissue Sarcoma(SarQuantIRM) | unknown | N/A | 25 | Centre Leon BerardOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT00919269 | Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma | completed | — | 150 | Children's Oncology GroupNETWORK | 7 | Oct 3, 2023 | clinicaltrials |
| NCT03317457 | Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma(MEDISARC) | completed | Phase 2 | 103 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04138381 | Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)(SeliGIST) | unknown | Phase 1 / Phase 2 | 30 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT01949506 | (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas | completed | N/A | 9 | Medical College of WisconsinOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT00354835 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma | completed | Phase 3 | 481 | Children's Oncology GroupNETWORK | 6 | Jan 31, 2023 | clinicaltrials |
| NCT03590210 | Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas(NiTraSarc) | completed | Phase 2 | 92 | University Medicine GreifswaldOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01462630 | Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma | completed | Phase 2 | 29 | Fox Chase Cancer CenterOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT01014598 | Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis | completed | Phase 1 | 11 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02357810 | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | completed | Phase 2 | 178 | Northwestern UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT00346164 | Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma | completed | Phase 3 | 588 | Children's Oncology GroupNETWORK | 5 | Apr 28, 2022 | clinicaltrials |
| NCT02048722 | Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT02050919 | Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT01532687 | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT01034566 | Proton Beam Radiation Therapy in Treating Patients With Retroperitoneal Sarcoma | withdrawn | N/A | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT02379845 | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall | completed | Phase 2 / Phase 3 | 180 | NanobiotixINDUSTRY | 13 | Apr 6, 2021 | clinicaltrials |
| NCT04765228 | Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma | unknown | Phase 2 | 45 | Yong ChenOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02520128 | A Study of IMRT in Primary Bone and Soft Tissue Sarcoma(IMRiS) | completed | N/A | 191 | University College, LondonOTHER | 2 | Dec 2, 2020 | clinicaltrials |
| NCT01433068 | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity | completed | Phase 1 | 22 | NanobiotixINDUSTRY | 1 | Oct 6, 2020 | clinicaltrials |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | terminated | Phase 2 | 89 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03613259 | Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jun 9, 2020 | clinicaltrials |
| NCT01446809 | Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma | completed | N/A | 23 | University of WashingtonOTHER | 1 | Apr 13, 2020 | clinicaltrials |
| NCT03121833 | Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma | completed | Phase 2 | 52 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT02180698 | TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT02849366 | Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01782313 | A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas | completed | Phase 2 | 58 | Northwestern UniversityOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT00484341 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. | completed | Phase 2 | 69 | AGC Biologics S.p.A.INDUSTRY | 3 | Aug 29, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Nov 30, 2017 | clinicaltrials |
| NCT01169350 | 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01055314 | Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma | completed | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 4 | Aug 29, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT03121846 | Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy | unknown | Phase 2 | 80 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 22, 2017 | clinicaltrials |
| NCT01222715 | Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 4 | May 5, 2017 | clinicaltrials |
Data updated 22 days agoSource updated May 15, 2026source: clinicaltrials